

# A Comparative Evaluation of Antimicrobial Coated versus Non-antimicrobial Coated Peripherally Inserted Central Catheters on Associated Outcomes: A Randomized Controlled Trial.

Susan Storey, PhD, RN; Jamie Brown MSN, RN; Angela Foley, MSN, RN; Erica Newkirk, MSN, RN; Jan Powers, PhD, RN; Julie Barger, BSN, RN; & Karen Paige MEd, BSN, RN.

Corresponding author: Susan Storey, PhD, RN, AOCNS; Assistant Scientist, Indiana University School of Nursing, Indianapolis, IN. 4602

[sustorey@iu.edu](mailto:sustorey@iu.edu)

## Highlights

- A randomized control trial of two types of PICC lines on the outcomes is described.
- No difference was noted in outcomes among the two types of PICC lines.
- Larger randomized control trials should be conducted to test these results.

## Abstract

**INTRODUCTION:** Central line associated blood stream infections (CLABSIs) are a common life-threatening risk factor associated with central venous catheters (CVCs). Research has demonstrated benefit in reducing CLABSI's when CVC's coated with antimicrobials are inserted. The impact of chlorhexidine (CHG) impregnated versus non-CHG PICCs on risk of CLABSI is unknown. Venous thromboembolism (VTE) is also a complication associated with CVCs. This study compares the impact of both PICC lines on these outcomes.

**METHODS:** Patients in 3 high risk units were randomly assigned to receive either a CHG impregnated or non-CHG PICC line. Laboratory data was collected and reviewed daily on all study patients. The PICC dressing site was assessed daily. Medical record documentation was reviewed to determine presence of CLABSI and/or VTE.

**RESULTS:** 167 patients completed the study. Three patients developed CLABSI (2 in the CHG and 1 non-CHG) and 3 patients developed VTE (2 in the non-CHG and 1 in the CHG PICC. No significant relationship was noted between the type of PICC line on development of a CLABSI ( $p = .61$ ) or VTE ( $p = 1.00$ ). A significant difference was noted in moderate bleeding ( $p = < .001$ ) requiring thrombogenic dressing in the patients who had the CHG PICC line.

**CONCLUSION:** No differences were noted in the development of CLABSI and VTE between the CHG and non-CHG groups.

Central venous catheters (CVCs) are important in the medical management of acutely ill patients. The most common and life-threatening complication of CVCs is the risk for a central line associated related blood stream infection (CLABSI). CLABSIs are preventable and when they occur during hospitalization, they are considered to be a hospital acquired infection (HAI). Subsequently, they impact patient outcomes and reimbursement of hospitalization costs from the Centers for Medicare and Medicaid Services, as well as private insurance companies. It is estimated in the United States (U.S.) that 1 of 20 hospitalized patients will develop a HAI.<sup>1</sup> CLABSIs are the third leading cause of HAIs, following catheter associated urinary tract infections and surgical site infections.<sup>2</sup>

According to the Joint Commission (2012), 3 million central lines are used each year.<sup>3</sup> It is estimated that 41,000 CLABSIs occur in U.S. hospitals each year with approximately 18,000 occurring in the intensive care unit (ICU) and 23,000 in non-ICU populations.<sup>3</sup> CLABSIs are costly and associated with poor patient outcomes such as increased length of stay, hospital costs and mortality.<sup>4,5</sup> It is estimated that CLABSI's cost the healthcare system approximately \$16,550 per episode,<sup>6</sup> and are associated with a mortality rate of 15-25%.<sup>7</sup> Reducing CLABSIs is a priority for improving patient safety and reducing healthcare costs.

Peripherally inserted central catheters (PICCs) are CVCs inserted, via ultrasonographic technique, into the upper veins of the arm with the tip advanced to the superior vena cava. PICC lines provide intravenous access for the administration of parenteral fluids, medications, blood products and nutrition as well as providing venous access for phlebotomy. PICC lines are a commonly used CVC, especially for patients requiring longer-term intravenous access. As with all CVCs, CLABSI is a potential risk in patients with PICC lines. Risk factors for the development of CLABSI include the number of times the line is manipulated, location of insertion,<sup>8</sup> and prolonged dwell time,<sup>9, 10</sup> and the development of thrombus.<sup>11</sup> Trauma and critical care patients, as well as those admitted with immune suppression are at an increased risk for CLABSI.<sup>12,13</sup>

In addition to the risk of CLABSI associated with PICC lines, upper extremity venous thromboembolism (VTE) is another potential complication.<sup>14, 15</sup> One study found 5% of hospitalized patients develop a symptomatic upper extremity VTE post PICC line insertion.<sup>16</sup> VTEs related to PICC lines present a challenge in clinical practice as it may interrupt and/or delay the patient's medical treatment plan. Factors associated with the development of VTE include catheter size, vein selection,<sup>14</sup> and number of insertion attempts.<sup>17</sup> In addition, researchers acknowledge there may be a reciprocal relationship where infection promotes thrombus formation or the presence of thrombus may facilitate the development of an infection.<sup>15,18</sup> Increased morbidity, hospital costs and length of stay have been associated with PICC related CLABSI and VTE.<sup>4, 5</sup>

One of the most important aspects in the prevention of CLABSIs is the care and maintenance of the line. Evidence-based bundles for insertion and maintenance care have been developed to prevent CLABSIs. These include insertion techniques such as: maximum sterile

barriers, site preparation and disinfection using chlorhexidine (CHG), sterile insertion procedures (mask, gown and gloves) and avoidance of femoral site selection.<sup>3</sup> In addition to these interventions, the use of antimicrobial or antimicrobial impregnated catheters has been recommended if there is no change in CLABSI rate after the implementation of evidence-based bundles<sup>13</sup> Research has demonstrated significant benefit in reducing CLABSIs when antimicrobial (chlorhexidine/silver sulfadiazine) or antibiotic (minocycline/rifampin) CVC's are inserted. A meta-analysis of randomized control trials (RCTs), demonstrated antimicrobial impregnated CVC's were associated with a decrease in bacterial colonization and CLABSI.<sup>19</sup> However, the majority of the studies included in the meta-analysis, focused on CVCs located in the femoral, subclavian and jugular veins. There is a paucity of research related to the impact of antimicrobial impregnated PICC lines, on the development of CLABSIs and/or VTE.

In 2011, the United States Food and Drug Administration approved PICC line impregnated with chlorhexidine (CHG) was introduced with clearance as a device with antimicrobial and anti-thrombogenic protection demonstrated for a minimum of 30 days.<sup>20</sup> Although this device does not contain heparin, it has been shown to have anti-thrombogenic properties.<sup>20</sup> Two publications<sup>21, 22</sup> noted decreases in CLABSI rates when the CHG impregnated antimicrobial PICC line was utilized, but did not examine its impact on the development of VTE. One of the publications described the findings from a quasi-experimental study, while the other was a 2-year product evaluation.<sup>21, 22</sup> To our knowledge, no RCTs have been conducted to examine the impact of CHG PICC lines. Therefore, the purpose of this study was to compare an antimicrobial PICC line impregnated with CHG to a non-CHG impregnated PICC line on the development of CLABSI and/or VTE among high risk hospitalized patients in the cardiovascular thoracic, medical intensive care (MICU) and oncology units.

## METHOD

### *Study Setting and Design*

This study was conducted over 18 months at a large, 800 bed tertiary community hospital in the Midwest. The study was approved by the hospital's Institutional Review Board. To reduce the potential for bias, both the CHG and non-CHG PICC lines were purchased by the institution. Three units were chosen for study recruitment due to higher CLABSI rates than other units in the hospital. Patients were enrolled in the study if they met the following inclusion criteria: a) required PICC line insertion on the cardiovascular thoracic, cardiovascular thoracic, MICU or oncology units; b) inpatient  $\geq 18$  years of age; c) no allergy to CHG; d) required insertion of a single or double lumen PICC line (the study PICC did not have a triple lumen option); e) anticipated hospital length of stay  $> 48$  hours. Patients were excluded from the study for: a) pregnancy and b) difficult PICC insertion requiring placement in vascular lab. Patients were notified upon consent that if their hospital length of stay or duration of the PICC line was in less than 48 hours they would be excluded from the study.

### *Sample*

Convenience sampling was utilized along with stratified sampling to ensure an equal number of participants came from each of the 3 designated study units. Target enrollment was set at 60 subjects (30 subjects in the control group and 30 subjects in the standard of care group) from each of the 3 units for a total of 180 subjects. To reduce bias, randomization was conducted by a third party who randomly mixed and selected envelopes containing study assignment group for each unit. Sixty envelopes per unit were divided evenly (30 in each group) and randomly assigned to either group A (CHG PICC) or B (non-CHG). The randomized envelope(s) were selected and placed in the enrollment folder.

### *Procedures*

After informed consent was obtained, patients were randomly assigned to receive either the CHG impregnated antimicrobial PICC or the non-CHG PICC . The non-CHG PICC was the standard of care at the facility at the time of the study. Both PICC lines were power-injectable.

The PICC lines were inserted by the hospital's specially trained PICC team. There are specific differences in the insertion technique between the two types of PICC lines. To ensure competency and consistency in placement, all PICC team members completed training on the insertion of the CHG impregnated antimicrobial PICC prior to study initiation. Standard procedures were followed for insertion of both types of PICC lines. Post-insertion, the PICC team documented type of PICC placed (CHG or non-CHG), catheter size, number of lumens, insertion date, time and initials of PICC team member responsible for insertion. The PICC team also documented post-insertion location, amount and extent of post insertion bleeding and if application of thrombogenic dressing or pressure dressing was required.

### *Data Collection*

Demographic information was collected at the time of enrollment and included: gender, age, unit location and duration of PICC line. The type of PICC line (CHG or non-CHG), insertion location and number of catheter lumens were also collected. Daily inspection of the PICC dressing and site was conducted by a study investigator to assess for signs and symptoms of infection and VTE. The assessment for infection included daily observation and documentation of dressing integrity and appearance of insertion site for presence of redness, warmth, edema, purulent drainage, and bleeding. To control for variations in technique, patients in the study had PICC dressing changes completed by the PICC team nurses or study investigators. PICC team nurses and study investigators attended a training review session with

return demonstration to assure standard practice and competency in dressing change techniques prior to study initiation.

Medical information on diagnosis, co-morbidities, laboratory and diagnostic tests results were collected on study subjects who developed a CLABSI or VTE, the outcomes of interest. When available, complete blood counts, specifically white blood cell, absolute neutrophil count (ANC), and platelets were reviewed to assess immune status and risk for bleeding in subjects who developed CLABSI or VTE. Laboratory-confirmed CLABSIs not secondary to an infection at another body site, were reviewed and verified by one certified infection prevention specialists based on the criteria established in the Center for Disease Control (CDC) guidelines (CDC, 2015). The laboratory identified the organism from the culture was also recorded. All patients were tracked for development of venous thromboembolism (VTE) in the upper extremity where the PICC line was placed. Venous thromboembolism was identified through clinical assessment of symptoms and diagnostic tests as ordered per standard practice for suspected occurrence. Post-insertion bleeding was defined as either moderate or severe dependent on the type of dressing required to control the bleeding. Moderate bleeding was defined as the need for application of a thrombogenic dressing. Severe bleeding was defined as bleeding that could not be controlled with the use of a thrombogenic dressing and required the application of a pressure dressing.

#### *Statistical Analysis*

An a priori sample size calculation was conducted using the average CLASI infection rate for the three selected units, a power of .80, and an alpha level of .05. Based on these numbers, a minimum sample size of 60 patients per unit (30 control and 30 experimental) was needed. Data were analyzed using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY). All tests were two-tailed and an alpha level of  $< .05$  was considered statistically

significant. Descriptive statistics were used to describe the sample. Data were checked for normality using the Shapiro-Wilk test. The Mann Whitney *U* test was used to assess differences in patient age and duration of PICC lines. Fisher's exact tests were used to assess for associations between the groups for the following outcomes: CLABSI, VTE and severity of post insertion bleeding. In addition, a Fisher's exact test was used to determine if there was a significant difference in the post insertion bleeding rate between the three hospital units.

## **RESULTS**

### *Sample characteristics*

One hundred eighty-nine subjects consented for participation and one hundred sixty seven completed the study. Twenty-two patients were withdrawn from the study, most due to not meeting the inclusion criteria of being hospitalized for at least 48 hours. See Figure 1 for the study flow diagram. The majority of study subjects were male. The majority of PICC lines placed in the study subjects were 5- French, double lumen, and placed in the basilic vein. No statistically significant differences were noted in the demographic or participant characteristics between the two groups. See Table 1. The study was discontinued after 18 months because of slow enrollment from the cardiovascular thoracic unit due to the frequent need for triple lumen PICC placement in which at the time of the study was not available in CHG PICC product line.

### *Central line associated bloodstream infection*

Results demonstrated no significant difference between the type of PICC line and the development of infection (Table 2). Three patients developed a CLABSI, two from the CHG group and one from the non-CHG group. The medical diagnoses of these subjects were: lymphoma ( $n = 1$ ) and acute myeloid leukemia ( $n = 2$ ). The median duration of the PICC lines prior to CLABSI in these three subjects was 18 days. The median number of days the three



subjects were neutropenic, defined as an absolute neutrophil count (ANC) < 500 cells/mm<sup>2</sup>, was

19. Organisms identified in these CLABSI's were *Klebsiella pneumoniae*, *Streptococcus viridans* and *Kocuria species* (gram + cocci).

#### *Venous thromboembolism*

Results demonstrated no significant relationship between the type of PICC line and the development of VTE (Table 2). Three subjects developed VTE, one in the CHG group and two in the non-CHG group. All of the patients who developed VTE were in the MICU. The medical diagnoses for the three subjects were ischemic bowel disease, ovarian cancer and hypotension. The median duration of the PICC lines prior to the development of VTE was 5 days. All of the study subjects had double lumen, 5 French catheter size PICC lines inserted. The subjects that developed VTE, all had the PICC lines inserted in the basilic vein (2 in the right and 1 in the left). *Post-insertion bleeding*

The majority (96%) who had post insertion bleeding were in the CHG PICC group. Subjects with the CHG PICC experienced moderate bleeding requiring application of a thrombogenic dressing more often compared to those with the non-CHG PICC line. (Table 2). No difference in post-insertion bleeding was noted among the 3 units ( $p = .97$ ).

Severe bleeding requiring the application of a pressure dressing occurred more often in subjects with the CHG PICC. Six of the subjects experienced severe post insertion bleeding requiring application of a pressure dressing. Of those, 5 (83%) of the subjects had the CHG PICC line.

## **DISCUSSION**

### *Central line associated bloodstream infection*

In this sample, no difference was noted in the development of CLABSI between the non-CHG and CHG PICC line study groups. Three patients from the oncology unit developed a CLABSI. Oncology patients present a unique challenge as they frequently experience immune suppression (neutropenia) as a result of treatment, leaving them vulnerable to infection.<sup>12</sup> Patients with hematologic cancers are susceptible to more days of neutropenia and subsequent infections.<sup>23</sup> Although this patient population has an increased risk of CLABSI, in this study other subjects with these hematologic diagnoses and similar characteristics were randomized to both types of PICC lines and did not develop CLABSI. Suggesting as others have noted, that the care and maintenance of the PICC line may impact the development of CLABSI perhaps more than the type of PICC line used.<sup>4</sup>

Other studies noted findings contrary to the findings of this study. In a quasi-experimental study of 260 patients receiving the CHG PICC (intervention) compared to 257 patients who received the non-CHG PICC (historical control), the authors noted those with the CHG PICC line had less CLABSIs than those with the non-CHG PICC line ( $p = .013$ ).<sup>21</sup> These findings however, need to be interpreted taking into consideration that this type of study design is less rigorous than an RCT and is more susceptible to bias. Additionally, the findings may have been influenced by differences in the patient population and/or changes in management of patients between the two time periods.

A quality improvement project conducted over a 2 year period, evaluated the CHG PICC line in 100 patients at a long-term acute care hospital. The authors reported no patients developed a CLABSI during the evaluation time period.<sup>22</sup> Quality improvement initiatives, while important, cannot be considered a robust research design and the findings must be interpreted with caution.

### *Venous thromboembolism (VTE)*

The 3 subjects who developed a PICC line associated VTE were from the MICU and had 5 French PICC lines inserted in the basilic vein. In other studies, VTE has been shown to be associated with catheter size; specifically researchers have shown the risk increases with catheter sizes  $\geq 5$  French. Patients with PICC catheter sizes 5 French and 6 French were found to have an earlier onset of VTE than patients with smaller size PICC lines.<sup>11</sup> Evans and colleagues found a correlation between catheter size and incidence of VTE when progressing from smaller 4 French (0.6%) to 5-Fr (2.9%) to larger 6 French (8.8%) PICC lines.<sup>6</sup>

Location of vein chosen for PICC insertion has been shown as a contributing factor for VTE. Researchers noted PICC lines inserted into the basilic vein were associated with higher incidence (3.1%) of VTE than those that are inserted into the cephalic or brachial veins.<sup>14</sup> Location of the catheter insertion has been noted as a predisposing factor to the development of VTE. In a retrospective review of 400 cases, those with left-sided catheter insertion were noted to be more likely to develop a VTE.<sup>5</sup> The authors suggest the longer left innominate vein may be the reason for this finding.<sup>5</sup>

Mechanically ventilated patients have also been identified at higher risk for VTE due to decreased cardiac output particularly in the presence of hypovolemia impaired cardiovascular reflexes and/or venous stasis.<sup>24, 25</sup> Information on the subjects as it relates to the status of mechanical ventilator use was not collected or analyzed. Despite these risk factors, no statistically significant difference was noted in the development of VTE between the CHG or non-CHG PICC groups.

### *Post insertion bleeding*

The CHG PICC line has demonstrated anti-thrombogenic properties for up to 30 days in clinical testing and post insertion bleeding is a known potential side effect.<sup>20</sup> Thirty-three (20%) subjects experienced post insertion bleeding. In this study, moderate bleeding requiring the application of a thrombogenic dressing occurred more often in subjects with the CHG PICC. The findings in this study are similar to another study where post insertion bleeding occurred in 30% of patients.<sup>22</sup> For the majority of patients the bleeding was resolved by the use of a thrombogenic dressing, however, in 6 (18%) instances severe bleeding occurred requiring the application of a pressure dressing.

### *Limitations*

Limitations of this study include the small sample size and single institution location. The lack of statistical significance between groups for CLABSI and VTE could be due to insufficient power. Post hoc power analysis showed the study obtained a power of only 48.9 % and that to have a study powered sufficiently to find a statistical difference with the infection rate found in the study would require a sample size of 348 (174 in each group).

Blinding of the study was not possible as the catheters differ in appearance and may have introduced bias into the study. It is possible that nurses (and patients) may have been more conscientious in the care and maintenance of the PICC lines because of their participation in the study. Another limitation of the study is that minimal demographic and patient characteristic information were collected on the participants. It is possible that there may have been significant differences between the groups despite the use of randomized group assignment. Therefore, it is recommended that potential confounders like diagnosis, severity of illness, and co-morbidities, be collected in future studies.

### *Strengths*

These limitations notwithstanding, this study had important strengths, such as the study design. To our knowledge this is the first RCT examining the effect of CHG impregnated antimicrobial PICC lines versus non-CHG PICC lines on the development of CLABSI and/or VTE. The inclusion of three high risk units (cardiovascular thoracic, MICU and oncology) with diverse patient populations is an additional strength of the study. Lastly, the utilization of a dedicated team for insertion, daily assessment and dressing changes of the PICC lines reduced the risk of variations in clinical practice techniques. The use of one infection prevention specialist for verification of CLABSIs reduced inter-rater reliability in this study.

### **CONCLUSION**

In this study, no difference was noted in CLABSI or VTE between patients who received the CHG or non-CHG PICC line. More patients with the CHG PICC line had post insertion bleeding requiring the application of a thrombogenic dressing and in some instances a pressure dressing. Additional RCT's with larger samples from multiple acute care hospitals are warranted to validate the findings of this study.

## REFERENCES

1. US Centers for Disease Control and Prevention. A better snapshot of HAIs and antibiotics used to treat them. 2011. Available from <http://www.cdc.gov/hai/eip/pdf/ASPS-Factsheet.pdf>. Accessed May 28<sup>th</sup>, 2015.
2. US Department of Health and Human Services. HHS Action Plan to Prevent Healthcare-Associated Infections. 2009. Available from <http://www.hhs.gov/ash/initiatives/hai/introduction.html> Accessed Mar 16, 2012.
3. US Centers for Disease Control and Prevention. Vital signs: Central line–associated blood stream infections—United States, Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention. 2008; 29:11. doi: 10.1016/j.ajic.2010.11.005
4. Kim JS, Holtom P, Vigen C. Reduction of catheter-related bloodstream infections through the use of a central venous line bundle: Epidemiologic and economic consequences. American Journal of Infection Control. 2001; 39: 640-6. doi: 10.1016/j.ajic.2010.11.005
5. Marnejon T, Angelo D, Abdou AA, Gemmel D. Risk factors for upper extremity venous thrombosis associated with peripherally inserted central venous catheters. Journal of Vascular Access. 2001;13: 231-238. doi: 10.5301/jva.5000039
6. Evans G. CLABSI prevention success pressures hospitals to adopt similar programs. Hospital Infection Control & Prevention. 2011; 38:37-41
7. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, Goeschel C. An intervention to decrease catheter-related bloodstream infections among intensive care patients in the ICU. New England Journal of Medicine. 2006; 355: 2725-2732.


8. Lorente L, Lecuna M, Ramos MJ, Jimenez A, Mora ML, Sierra A. Lower associated costs using rifampicin-miconazole-impregnated catheter compared with standard catheters. *American Journal of Infection Control*. 2011; 39:895-897. Doi: 10.1016/j.ajc.2011.01.018
9. Mermel LA. Prevention of intravascular catheter-related infections. *Journal of Hospital Infection*. 2007; 65:30-33.
10. Timsit J, Heriteau FL, Lepape A, Francais A, Ruckly S, Venier AG, Savey A. A multicenter analysis of catheter-related infection based on a hierarchical model. *Intensive Care Medicine*. 2012; 38:1662-1672. doi:10.1007/s00134-012-2645-6
11. Chopra V, Ratz D, Kuhn L, Lopus T, Lee A, Krein S. Peripherally inserted central catheter-related deep vein thrombosis: Contemporary patterns and predictors. *Journal of Thrombosis and Haemostasis*. 2014; 12: 847-854. Doi: 10.1111/jth.12549
12. Schwartzberg LS. Neutropenia: Etiology and pathogenesis. *Clinical Cornerstone*. 2006; 8: S5–S11.
13. O’Grady NP, Alexander M, Burns A, Dellinger EP, Garland J, Heard SO, Saint S. Summary of recommendations: Guidelines for the prevention of intravascular catheter-related infections. *Clinical Infectious Disease*. 2011; 52:1087-1099. doi:10.1093/cid/cir.138
14. Liem TK, Yanit KE, Moseley SE, Landry GJ, DeLoughery TG, Rumwell CA, Moneta GL. Peripherally inserted central catheter usage patterns and associated symptomatic upper extremity venous thrombosis. *Journal of Vascular Surgery*. 2012; 55: 761-767. doi:10.1016/j.jvs.2011.10.005

15. Clemence BJ, Maneval RE. Risk factors associated with catheter-related upper extremity deep vein thrombosis in patients with peripherally inserted central venous catheters: Literature review: Part 1. *Infusion Nurses Society*. 2014; 37:187-196. Doi: 10.1097/NAN.0000000000000037
16. Lobo B, Vaidean G, Broyles J. et al. Risk of venous thromboembolism in hospitalized patients with peripherally inserted catheters. *Journal of Hospital Medicine*. 2009; 4: 417-422.
17. Lee A, Levine M, Julian J, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. *Journal of Clinical Oncology*. 2006; 24:1404-1408.
18. Mehall JR, Saltzman DA, Jackson RJ, Smith SD. Fibrin sheath enhances central venous catheter infections. *Critical Care Medicine*. 2002; 30: 908-912.
19. Falagas ME, Fragoulis K, Blitziotis IA., Chatzinikolaou I. Rifampicin-impregnated central venous catheters: A meta-analysis of randomized controlled trials. *Journal of Antimicrobial Chemotherapy*. 2007; 59: 359-369. doi:10.1093/j.ac/dk1522
20. Teleflex Medical receives FDA 510(k) clearance for antithrombogenic claims on its ARROW<sup>®</sup> peripherally inserted central catheter (PICC) with Chlorgar+ard<sup>®</sup> technology [press release]. Research Triangle Park, NC: Teleflex Medical; May 21, 2012. Available from [http://www.businesswire.com/news/home/20120521006340/en/Teleflex-Recieves-FDA-510-Clearance-Antithrombogenic -Claims](http://www.businesswire.com/news/home/20120521006340/en/Teleflex-Recieves-FDA-510-Clearance-Antithrombogenic-Claims). Accessed June 10, 2015.
21. Rutkoff GS. The influence of an antimicrobial peripherally inserted central catheter on central line-associated bloodstream infections in a hospital environment. *Journal of the Association for Vascular Access*. 2014; 19: 172-179. doi:10.1016/j.java.2014.06.002



22. Tavianini HD, Deacon V, Negrete J, Salapka S. Up for the challenge: Eliminating peripherally inserted central catheter infections in a complex patient population. *Journal of the Association for Vascular Access*. 2014;19:159-164. doi: 10.1016/j.java.2014.05.004
23. US Center for Disease Control and Prevention. (2015). Bloodstream infection event (Central line-associated blood stream infection and non-central line-associated blood stream infection. Available from [http://www.cdc.gov/nhsn/PDFs/pscManual/4PSC\\_CLABScurrent.pdf](http://www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScurrent.pdf). Accessed on October 24, 2015.
24. Lustberg M. Management of neutropenia in cancer patients. *Clinical Advances in Hematology Oncology*. 2012; 10: 825-826.
25. Cook D. Deep vein thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. *Critical Care Medicine*. 2005; 33:1565-1571.
26. Luce JM. The cardiovascular effects of mechanical ventilation and positive end-expiratory pressure. *JAMA*. 1984; 252: 807-811.

Figure 1. Study flow diagram



\*At time of the study, the triple lumen Chlorhexidine PICC was not available.

Table 1. Comparison of Demographic and Participant Characteristics

<b>Characteristic</b>	<b>Chlorhexidine PICC (n = 80)</b>	<b>Non- Chlorhexidine PICC (n = 87)</b>	<b>p value</b>
	<b>N (%)</b>	<b>N (%)</b>	
Gender	95 (57)	72 (43)	.76
Study unit			
Medical Intensive Care Unit	28	31	.71
Cardiovascular Thoracic Unit	21	27	
Oncology Unit	29	31	
PICC type			
5 Fr	74 (90.2)	77 (90.6)	1.0
Other	8 (9.8)	8 (9.4)	
PICC location			
Basilic vein	13 (15.9)	17 (20.0)	.55
Other	69 (84.1)	68 (80.0)	
Number of lumens			
Double	79	77	.20
Single	3	8	
	<b>Mdn (IQR)</b>	<b>Mdn (IQR)</b>	
Age (years)	62 (22)	64 (21)	.42
Duration of PICC line (days)	8 (8)	8 (8)	.86

Table 2. Comparison of outcomes by PICC group ( $N = 167$ )

Outcome	<b>Chlorhexidine PICC (<math>n = 80</math>)</b>	<b>Non-Chlorhexidine PICC (<math>n = 87</math>)</b>	
	<b><i>N</i> (%)</b>	<b><i>N</i> (%)</b>	<b><i>p</i> value</b>
Central line associated blood stream infection	2 (2.5)	1 (1.1)	.067
Venous thromboembolism	1 (1.3)	2 (2.2)	1.000
Moderate bleeding requiring use of thrombix dressing	26 (32.5)	1 (1.1)	< .001
Severe bleeding requiring pressure dressing	5 (6.3)	1 (1.1)	.105